New pill HRS-2129 aims to ease knee arthritis pain
NCT ID NCT07351968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called HRS-2129 in 200 people with moderate to severe knee osteoarthritis pain. Participants will receive either HRS-2129, a placebo, or an active comparator (celecoxib) to see if it reduces pain and improves joint function. The study is double-blind, meaning neither patients nor doctors know who gets what, to ensure unbiased results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-2129 tablet
- What this could lead to
- If successful, this could lead to a new pain relief option for people with knee osteoarthritis.
- What could go wrong
- This is an early Phase 1 study with only 200 people, so it's too soon to know if HRS-2129 works or is safe. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE AND SEVERE PAIN IN KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Drum Tower Hospital affiliated to Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, 210005, China